Comparison of clinical prognosis between stereotactic body radiotherapy and surgical treatment for early-stage non-small cell lung cancer after propensity score matching
Dong Baiqiang, Wang Jin, Xu Yujin, Die Xiaoyun, Shan Guoping, Chen Weijun, Chen Mengyuan, Zheng Lei, Li Pu, Li Jianlong, Shao Kainan, Chen Ming
Wenzhou Medical University,Wenzhou 325000,China (Dong BQ,Chen M):Department of Radiation Oncology (Wang J,Xu YJ,Chen MY,Zheng L, Chen M),Department of Radiation Physics (Di XY,Shan GP,Chen WJ, Li P,Li JL,Shao KN),Department of Oncology Surgery (Zheng L), Zhejiang Cancer Hospital,Hangzhou 310000,China;Zhejiang Key Laboratory of Radiation Oncology,Hangzhou 310000,China (Wang J,Xu YJ, Di XY,Shan GP,Chen WJ,Chen MY,Li P,Li JL,Shao KN)
Abstract：Objective To evaluate the clinical efficacy between stereotactic body radiotherapy (SBRT) and surgical treatment for stage Ⅰ-Ⅱ non-small cell lung cancer (NSCLC). Methods Clinical data of 120 patients with early-stage NSCLC who underwent SBRT or surgical treatment in Zhejiang Cancer Hospital from 2012 to 2015 were retrospectively analyzed. Propensity score matching was carried out between two groups. Sixty eligible patients were enrolled in each group. In the SBRT group,the 80% isodose line covered 95% of the planning target volume,and the 100% isodose line covered 100% of the internal gross tumor volume. The fractional dose was 5-15 Gy and the median biologically equivalent dose was 100 Gy (range:57.6-150.0 Gy).In the operation group,32 patients underwent video-assisted thoracoscopic lobectomy and 9 patients underwent wedge resection or segmentectomy. Results All patients successfully completed corresponding treatment and were followed up. The median follow-up was 32.3 months (range:8.6-68.4 months).In the operation group,3 patients died from infection within postoperative 90 d,whereas no case died in the SBRT group (P=0.079).In the SBRT group,3 patients died of other factors besides tumor (cerebral infarction,heart disease,etc.) during follow-up. Local-regional recurrence occurred in 12 patients including 5 cases in the operation group and 7 in the SBRT group (P=0.543).In the operation group,11 patients experienced distant metastases with a median disease-free survival (DFS) of 33.5 months. In the SBRT group,6 patients had distant metastases and the median DFS was 38.4 months (P=0.835,P=0.178).In the SBRT group,the 1-and 3-year overall survival rates were 93% and 83%,and 95% and 83% in the operation group (P=0.993). Conclusions The 1-and 3-year overall survival rates and local control rate do not significantly differ between SBRT and operation for patients with early-stage NSCLC.
Dong Baiqiang,Wang Jin,Xu Yujin et al. Comparison of clinical prognosis between stereotactic body radiotherapy and surgical treatment for early-stage non-small cell lung cancer after propensity score matching[J]. Chinese Journal of Radiation Oncology, 2018, 27(10): 890-894.
[1] Ettinger DS,Kris MG.NCCN:non-small cell lung cancer[J].Cancer Cont,2001,8(6 Suppl 2):22-31. [2] Palma D,Visser O,Lagerwaard FJ,et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage Ⅰ non-small-cell lung cancer:apopulation-based time-trend analysis[J].J Clin Oncol,2010,28(35):5153-5159.DOI:10.1200/JCO.2010.30.0731. [3] Onishi H,Shirato H,Nagata Y,et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for Stage I non-small cell lung cancer:updated results of 257 patients in a Japanese multiinstitutional study[J].J Thorac Oncol,2007,2(7 Suppl 3):S94-100.DOI:10.1097/JTO.0b013e318074 de34. [4] Nagata Y,Takayama K,Matsuo Y,et al. Clinical outcomes of a phase Ⅰ/Ⅱ study of 48 Gy in 4 fractions for primary lung cancer using a stereotactic body frame[J].Int J Radiat Oncol Biol Phys,2005,63(5):1427-31.DOI:10.1016/j.ijrobp.2005.05.034. [5] Uematsu M,Shoida A,Suda A,et al. Computed tomography-guided frameless stereotactic radiotherapy for stage Ⅰ non-small cell lung cancer:a 5-year experience[J].Int J Radiat Oncol Biol Phys,2001,51(3):666-670.DOI:10.1016/S0360-3016(01)01703-5. [6] Zimmermann FB,Geinitz H,Schill S,et al. Stereotactic hypo fractionated radiation therapy for stage Ⅰ non-small cell lung cancer[J].Lung Cancer,2005,48(1):107-114.DOI:10.1016/j.lungcan.2004.10.015. [7] Fakiris AJ,McGarry RC,Yiannoutsos CT,et al. Stereotactic body radiation therapy for early stage non-small cell lung carcinoma:Four-year results of a prospective phase Ⅱ study[J].Int J Radiat Oncol Biol Phys,2009,75(3):677-682.DOI:10.1016/j.ijrobp.2008.11.042. [8] Chi A,Liao Z,Nguyen NP,et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer:clinical implications[J].Radiother Oncol,2010,94(1):1-11.DOI:10.1016/j.radonc.2009.12.008. [9] Baumann P,Nyman J,Hoyer M,et al. Stereotactic body radiotherapy for medically inoperable patients with stage Ⅰ non-small cell lung cancer-a first report of toxicity related to COPD/CVD in a non-randomized prospective phase Ⅱ study[J].Radiother Oncol,2008,88(3):359-367.DOI:10.1016/j.radonc.2008.07.019. [10] Senan S,Gundy C,Haasbeek CJ,et al. Health-related quality of life (HRQOL) after stereotactic body radiotherapy (SBRT) for stage Ⅰ non-small cell lung cancer (NSCLC)[J].Clin Oncol,2010,28(15 Suppl):?-?.DOI:10.1200/jco.2010.28.15_suppl.7079. [11] Schulte T,Schniewind B,Walter J,et al. Agerelated impairment of quality of life after lung resection for non-small cell lung cancer[J].Lung Cancer,2010,68(1):115-120.DOI:10.1016/j.lungcan.2009.05.019. [12] Fernando HC,Timmerman R.American college of surgeons oncology group Z4099/radiation therapy oncology group 1021:a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage Ⅰ non-small cell lung cancer[J].J Thorac Cardiovasc Surg,2012,144(3):S35-S38.DOI:10.1016/j.jtcvs.2012.06.003. [13] Timmerman R,Paulus R,Galvin J,et al. Stereotactic body radiation therapy for inoperable early stage lung cancer[J].JAMA,2010,303(11):1070-1076.DOI:10.1001/jama.2010.261. [14] Hurkmans CW,Cuijpers JP,Lagerwaard FJ,et al. Recommendations for implementing stereotactic radiotherapy in peripheral stageⅠA non-small cell lung cancer:report from the quality assurance working party of the randomised phase Ⅲ ROSEL study[J].Radiat Oncol,2009,4:1.DOI:10.1186/1748-717X-4-1. [15] Onishi H, Araki T, Shirato H,et al. Stereotactic hypofractionated high dose irradiation for stage Ⅰ non-small cell lung carcinoma:clinical outcomes in 245 subjects in a Japanese multi-institutional study[J].Cancer,2004,101(7):1623-1631.DOI:10.1002/cncr.20539. [16] Chang JY,Senan S,Paul MA,et al,Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer:a pooled analysis of two randomised trials[J].Lancet Oncol,2015,16(6):630-7.DOI:10.1016/S1470-2045(15)70168-3. [17] Palma DA,Senan S.Improving outcomes for high-risk patients with early-stage non-small-cell lung cancer:insights from population-based data and the role of stereotactic ablative radiotherapy[J].Clin Lung Cancer,2013,14(1):1-5.DOI:10.1016/j.cllc.2012.06.005.
2018, Vol. 27 
